caa a22 4500 605537321 CHVBK 20210128100856.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s10517-015-3135-y doi (NATIONALLICENCE)springer-10.1007/s10517-015-3135-y Antiarrhythmic Activity of Taurepar during Ischemic and Reperfusion Damage to Myocardium [Elektronische Daten] [I. Krylova, V. Bul'on, E. Selina, N. Sapronov, P. Shabanov] The antiarrhythmic effect of taurepar, an N-phenylalkyl derivative of taurine, was examined in experiments on rats subjected to acute myocardial ischemia/reperfusion leading to arrhythmia development. During acute ischemia, taurepar (25 mg/kg) completely prevented early postocclusion arrhythmias including extrasystoles, ventricular tachycardia, and ventricular fibrillation. During postischemic reperfusion, taurepar (25 mg/kg) did not prevent extrasystoles and ventricular tachycardia, but precluded the development of ventricular fibrillation and the death of animals. The antiarrhythmic potency of taurepar surpassed that of lidocaine during acute myocardial ischemia and that of propranolol during ischemia/reperfusion injury. The results suggest that taurepar is a promising antiarrhythmic drug with high antifibrillation activity. Springer Science+Business Media New York, 2015 myocardium nationallicence ischemia nationallicence reperfusion nationallicence arrhythmias nationallicence taurepar nationallicence Krylova I. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut Bul'on V. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut Selina E. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut Sapronov N. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut Shabanov P. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 160/2(2015-12-01), 228-230 0007-4888 160:2<228 2015 160 10517 https://doi.org/10.1007/s10517-015-3135-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10517-015-3135-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Krylova I. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut NATIONALLICENCE 700 1- Bul'on V. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut NATIONALLICENCE 700 1- Selina E. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut NATIONALLICENCE 700 1- Sapronov N. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut NATIONALLICENCE 700 1- Shabanov P. Department of Neuropharmacology, Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia aut NATIONALLICENCE 773 0- Bulletin of Experimental Biology and Medicine Springer US; http://www.springer-ny.com 160/2(2015-12-01), 228-230 0007-4888 160:2<228 2015 160 10517